41. Roghmann MC, Qaiyumi S, Johnson JA, Schwalbe R, Morris JG. Recurrent vancomycin-resistant *Enterococcus faecium* bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. *Clin Infect Dis* 1997;24:514-515.
42. Lai KK, Fontecchio SA, Kelley AL, Melvin ZS, Baker S. The epidemiology of fecal carriage of vancomycin-resistant enterococci. *Infect Control Hosp Epidemiol* 1997;18:762-765.
43. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. *Infect Control Hosp Epidemiol* 1995;16:105-113.
44. Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. *Clin Infect Dis* 1995;21:45-50.
45. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. *J Infect Dis* 1995;172:993-1000.
46. Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. *Infect Control Hosp Epidemiol* 1995;16:577-581.
47. Anderson RL, Carr JH, Bond WW, Favero MS. Susceptibility of vancomycin-resistant enterococci to environmental disinfectants. *Infect Control Hosp Epidemiol* 1997;18:195-199.
48. Saurina G, Landmann D, Quale JM. Activity of disinfectants against vancomycin-resistant *Enterococcus faecium. Infect Control Hosp Epidemiol* 1997;18:345-347.
49. Bradley CR, Fraise AP. Heat and chemical resistance of enterococci. *J Hosp Infect* 1996;34:191-196.
50. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adal KA, Farr BM. Disinfection of hospital rooms contaminated with vancomycin-resistant *Enterococcus faecium. Infect Control Hosp Epidemiol* 1998;19:261-264.
51. Torell E, Fredlund H, Tornquist E, Myhre EB, Sjoberg L, Sundsfjord A. Intrahospital spread of vancomycin-resistant *Enterococcus faecium* in Sweden. *Scand J Infect Dis* 1997;29:259-263.
52. McNeil MM, Solomon SL. The epidemiology of methicillin-resistant *Staphylococcus aureus. Antimicrobic Newsletter* 1985;2:49-56.
53. Chow JW, Kuritza A, Shlaes DM, Green M, Sahm DF, Zervos MJ. Clonal spread of vancomycin-resistant *Enterococcus faecium* between patients in three hospitals in two states. *J Clin Microbiol* 1993;31:1609-1611.
54. Tenover FC, Tokars J, Swenson J, Paul S, Spitalny K, Jarvis W. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. *J Clin Microbiol* 1993;31:1695-1699.
55. Webb R, Currier M, Brackin B, Nolan R, Wilson J. Capability to identify vancomycin resistant enterococci (VRE) and other emerging pathogens in clinical microbiology laboratories serving a rural state. *Infect Control Hosp Epidemiol* 1997;18:(suppl)P23. Abstract.
56. Swenson JM, Ferraro MJ, Sahm DF, Charache P, the National Committee for Clinical Laboratory Standards Working Group on Enterococci, Tenover FC. New vancomycin disk diffusion breakpoints for enterococci. *J Clin Microbiol* 1992;30:2525-2528.
57. Swenson JM, Clark NC, Ferraro MJ, Sahm DF, Doern G, Pfaller MA, et al. Development of a standardized screening method for detection of vancomycin-resistant enterococci. *J Clin Microbiol* 1994;32:1700-1704.
58. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova, PA: National Committee for Clinical Laboratory Standards; 1993.
59. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A5. Villanova, PA: National Committee for Clinical Laboratory Standards; 1993.
60. Ribeiro J, Chenevert C, Miller N, Boyce J. Prevalence of vancomycin-resistant enterococci (VRE) among nursing home residents (NHR) admitted to a university-affiliated hospital. *Infect Control Hosp Epidemiol* 1997;18:(suppl)P23. Abstract.
61. Revuelta MP, Nord JA, Yarrish RL, Kislak JW, LaBombardi V. Recycling of hospital-acquired colonization with vancomycin resistant enterococci via nursing home residents. *Clin Infect Dis* 1995;21:730. Abstract.
62. Sargent SJ, Baselski VS, Reed LD, Wong L, Sahm DF. Simultaneous hospital and community emergence of vancomycin-resistant *Enterococcus faecium. Clin Infect Dis* 1995;21:729. Abstract.
63. Bates J. Epidemiology of vancomycin-resistant enterococcus in the community and the relevance of farm animals to human infection. *J Hosp Infect* 1997;37:89-101.
64. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. *Antimicrob Agents Chemother* 1996;40:2605-2609.
65. Semmelweis I. *The Etiology, the Concept, and the Prophylaxis of Childbed Fever.* Pest, CA: Hartlben's Verlag-Expedition; 1861. Translated by FP Murphy and republished, Classics of Medicine Library, Birmingham, AL; 1981.
66. Larson E, Kretzer EK. Compliance with handwashing and barrier precautions. *J Hosp Infect* 1995;30:88-106.
67. Jarvis WR. Handwashing—the Semmelweis lesson forgotten? Lancet 1994;344:1311-1312.
68. Voss A, Widmer AF. No time for handwashing!? Handwashing versus alcoholic rub: can we afford 100% compliance? *Infect Control Hosp Epidemiol* 1997;18:205-208.
69. Larson E, McGeer A, Quraishi A, Krenzischek D, Parsons BJ, Holdford J, et al. Effect of an automated sink on handwashing practices and attitudes in high-risk units. *Infect Control Hosp Epidemiol* 1991;12:422-428.
70. Maki DG, Zilz MA, McCormick R. The effectiveness of using pre-emptive barrier precautions routinely (protective isolation) in all high-risk patients to prevent nosocomial infection with resistant organisms, especially MRSA, VRE, and *C difficile.* The 34th Annual Meeting of the Infectious Diseases Society of America; New Orleans, LA; September 1996. Abstract 43.
71. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. *JAMA* 1996;275:234-240.
72. Centers for Disease Control and Prevention. Update: *Staphylococcus aureus* with reduced susceptibility to vancomycin—United States. *MMWR* 1997;46:813-815.

International Course in Applied Epidemiology

Gina Pugliese, RN, MS
Martin S. Favero, PhD

The CDC and Emory University will cosponsor a course in applied epidemiology designed for international public health professionals to be held at the CDC on October 5-30, 1998. The course emphasizes the practical application of epidemiology to public health problems and comprises lectures, workshops, classroom exercises (including actual epidemiological problems), and computer laboratories. Topics covered include descriptive epidemiology and biostatistics, analytic epidemiology, epidemic investigation, public health surveill ance, surveys and sampling, computers and Epi Info software, and discussions of selected prevalent diseases. There is a tuition charge.

Applications must be received by August 31, 1998. Additional information and applications are available from Department PSB, Rollins School of Public Health, Emory University, 7th Floor, 1518 Clifton Rd NE, Atlanta, GA 30322; telephone 404-727-3485; fax 404-727-4590; or e-mail ogostan@sph.emory.edu.

https://doi.org/10.1017/S0899823X00095295 Published online by Cambridge University Press